Publication

A state-of-the-art multi-criteria model for drug benefit-risk analysis

Tervonen, T., Hillege, H. L., Buskens, E. & Postmus, D., 2010, Groningen: University of Groningen, SOM research school, 22 p. (SOM Research Reports; vol. 10001).

Research output: Working paperAcademic

APA

Tervonen, T., Hillege, H. L., Buskens, E., & Postmus, D. (2010). A state-of-the-art multi-criteria model for drug benefit-risk analysis. (SOM Research Reports; Vol. 10001). Groningen: University of Groningen, SOM research school.

Author

Tervonen, T. ; Hillege, H.L. ; Buskens, E. ; Postmus, D. / A state-of-the-art multi-criteria model for drug benefit-risk analysis. Groningen : University of Groningen, SOM research school, 2010. (SOM Research Reports).

Harvard

Tervonen, T, Hillege, HL, Buskens, E & Postmus, D 2010 'A state-of-the-art multi-criteria model for drug benefit-risk analysis' SOM Research Reports, vol. 10001, University of Groningen, SOM research school, Groningen.

Standard

A state-of-the-art multi-criteria model for drug benefit-risk analysis. / Tervonen, T.; Hillege, H.L.; Buskens, E.; Postmus, D.

Groningen : University of Groningen, SOM research school, 2010. (SOM Research Reports; Vol. 10001).

Research output: Working paperAcademic

Vancouver

Tervonen T, Hillege HL, Buskens E, Postmus D. A state-of-the-art multi-criteria model for drug benefit-risk analysis. Groningen: University of Groningen, SOM research school. 2010. (SOM Research Reports).


BibTeX

@techreport{f8221a9319fd4aee8ae3fb98470d893c,
title = "A state-of-the-art multi-criteria model for drug benefit-risk analysis",
abstract = "Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy outcomes, such as tolerability, treatment response, and adverse events. In this paper, we propose a new approach for constructing a supporting multi-criteria model that fully takes into account this evidence. Our approach is based on the Stochastic Multicriteria Acceptability Analysis (SMAA) methodology, which allows us to compute the typical value judgments that support a decision, to quantify uncertainty, and to compute a comprehensive benefit-risk profile. As an example, we constructed a multi-criteria model for the therapeutic group of second-generation antidepressants. We analyzed Fluoxetine, Paroxetine, Sertraline, and Venlafaxine according to relative efficacy and absolute rates of several common adverse drug reactions using meta-analytical data from the literature. Our model showed that there are clear trade-offs among the four drugs. Based on our experiences from this study, SMAA appears to be a suitable approach for quantifying trade-offs and decision uncertainty in drug benefit-risk analysis.",
keywords = "risk communication, metaanalysis, simulation methods, decision analysis, clinical pharmacology",
author = "T. Tervonen and H.L. Hillege and E. Buskens and D. Postmus",
note = "Relation: https://www.rug.nl/ Rights: University of Groningen",
year = "2010",
language = "English",
volume = "10001",
series = "SOM Research Reports",
publisher = "University of Groningen, SOM research school",
type = "WorkingPaper",
institution = "University of Groningen, SOM research school",

}

RIS

TY - UNPB

T1 - A state-of-the-art multi-criteria model for drug benefit-risk analysis

AU - Tervonen, T.

AU - Hillege, H.L.

AU - Buskens, E.

AU - Postmus, D.

N1 - Relation: https://www.rug.nl/ Rights: University of Groningen

PY - 2010

Y1 - 2010

N2 - Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy outcomes, such as tolerability, treatment response, and adverse events. In this paper, we propose a new approach for constructing a supporting multi-criteria model that fully takes into account this evidence. Our approach is based on the Stochastic Multicriteria Acceptability Analysis (SMAA) methodology, which allows us to compute the typical value judgments that support a decision, to quantify uncertainty, and to compute a comprehensive benefit-risk profile. As an example, we constructed a multi-criteria model for the therapeutic group of second-generation antidepressants. We analyzed Fluoxetine, Paroxetine, Sertraline, and Venlafaxine according to relative efficacy and absolute rates of several common adverse drug reactions using meta-analytical data from the literature. Our model showed that there are clear trade-offs among the four drugs. Based on our experiences from this study, SMAA appears to be a suitable approach for quantifying trade-offs and decision uncertainty in drug benefit-risk analysis.

AB - Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy outcomes, such as tolerability, treatment response, and adverse events. In this paper, we propose a new approach for constructing a supporting multi-criteria model that fully takes into account this evidence. Our approach is based on the Stochastic Multicriteria Acceptability Analysis (SMAA) methodology, which allows us to compute the typical value judgments that support a decision, to quantify uncertainty, and to compute a comprehensive benefit-risk profile. As an example, we constructed a multi-criteria model for the therapeutic group of second-generation antidepressants. We analyzed Fluoxetine, Paroxetine, Sertraline, and Venlafaxine according to relative efficacy and absolute rates of several common adverse drug reactions using meta-analytical data from the literature. Our model showed that there are clear trade-offs among the four drugs. Based on our experiences from this study, SMAA appears to be a suitable approach for quantifying trade-offs and decision uncertainty in drug benefit-risk analysis.

KW - risk communication

KW - metaanalysis

KW - simulation methods

KW - decision analysis

KW - clinical pharmacology

M3 - Working paper

VL - 10001

T3 - SOM Research Reports

BT - A state-of-the-art multi-criteria model for drug benefit-risk analysis

PB - University of Groningen, SOM research school

CY - Groningen

ER -

ID: 15132575